Medical device company ICU Medical (NASDAQ:ICUI) reported Q2 CY2026 results beating Wall Street’s revenue expectations, but sales were flat year on year at $547.9 million. Its non-GAAP profit of $2.37 per share was 23.8% above analysts’ consensus estimates.
Is now the time to buy ICUI? Find out in our full research report (it’s free for active Edge members).
ICU Medical (ICUI) Q2 CY2026 Highlights:
- Revenue: $547.9 million vs analyst estimates of $532.8 million (flat year on year, 2.8% beat)
- Adjusted EPS: $2.37 vs analyst estimates of $1.91 (23.8% beat)
- Adjusted EBITDA: $110 million vs analyst estimates of $101.1 million (20.1% margin, 8.9% beat)
- Adjusted EPS guidance for the full year is $8.80 at the midpoint, beating analyst estimates by 7.8%
- EBITDA guidance for the full year is $425 million at the midpoint, above analyst estimates of $417 million
- Operating Margin: 11%, up from 4.9% in the same quarter last year
- Market Capitalization: $4.16 billion
StockStory’s Take
ICU Medical’s second quarter results were well received by the market, with management highlighting robust performance in the Infusion Systems and Consumables segments as key drivers. CEO Vivek Jain emphasized that North America led growth, and noted that “record quarters” in both pumps and consumables reflected broad-based demand and incremental wins. Operational efficiencies stemming from IT system integration and facility consolidation also contributed to improved operating margins. Management pointed out that ongoing challenges from currency fluctuations and tariffs were offset by core business execution and stable customer demand.
Looking to the remainder of the year, management’s updated guidance is underpinned by margin improvement initiatives, ongoing product innovation, and the anticipated completion of long-running integration projects. Jain stated that new product launches, particularly within the Plum Duo, Solo, and Medfusion pump lines, should support long-term revenue growth. CFO Brian Bonnell cautioned that oil prices and currency volatility remain risks, but expects operating expense reductions and realization of synergies to further support profitability. The company’s focus on innovation and operational discipline is designed to position ICU Medical for steady growth despite external headwinds.
Key Insights from Management’s Remarks
Management attributed the quarter’s outperformance to operational execution, balanced growth across core product lines, and the realization of synergies from integration initiatives.
-
Infusion Systems momentum: The Infusion Systems business delivered double-digit organic growth, with Jain crediting both earlier-than-expected installations and competitive wins for the strong performance. Management emphasized that the broader replacement cycle for infusion pumps has not yet begun in earnest, suggesting further upside potential.
-
Consumables segment strength: The Consumables business achieved record sales, with balanced growth across all four product families and solid demand from both hospital and home care settings. Jain noted that this growth was driven more by volume and new customer wins than by pricing.
-
Facility and IT integration benefits: CFO Brian Bonnell highlighted that operational efficiencies from IT system integration and consolidation of manufacturing and distribution centers contributed to lower selling, general, and administrative (SG&A) expense rates. These initiatives are expected to yield ongoing benefits in future quarters.
-
Tariff and currency headwinds: Management acknowledged continued challenges from tariff expenses and unfavorable movements in key currencies, especially the Costa Rican colon and Japanese yen. However, these were largely offset by lower tariff rates and increased core business profitability.
-
Vital Care stabilization: The Vital Care segment experienced sequential improvement after earlier SKU rationalization and product exits. Jain indicated that most of the impact from these actions is now reflected in results, and expects the segment to stabilize for the remainder of the year.
Drivers of Future Performance
Management’s outlook for the rest of the year is based on continued product innovation, margin expansion through cost controls, and stable demand in core markets.
-
Product innovation pipeline: Jain highlighted that ICU Medical is at the beginning of new product cycles, particularly for the Plum Duo, Solo, and Medfusion 5000 pumps. The company expects these launches to support predictable long-term revenue growth as they enable both competitive wins and upgrades of the existing installed base.
-
Margin improvement initiatives: Bonnell pointed to ongoing efforts to expand gross margins by capturing synergies from facility consolidation, incremental pricing, and product mix optimization. Management reiterated its goal of realizing two additional percentage points of gross margin, acknowledging that full achievement will take several quarters and is subject to external factors like tariffs and currency volatility.
-
Free cash flow and leverage goals: With strong free cash flow generation in the first half of the year, management reaffirmed its target of reaching a 2x net leverage ratio by year-end. This is expected to be supported by reduced cash spend on restructuring and remediation, as well as stable operating performance.
Catalysts in Upcoming Quarters
In the coming quarters, the StockStory team will watch closely for (1) continued momentum in Infusion Systems and Consumables product launches and upgrades, (2) sustained improvement in gross and operating margins from integration and cost initiatives, and (3) updates on the regulatory approval and commercial rollout of the Medfusion 5000 pump. Progress toward achieving leverage and free cash flow targets will also be critical for tracking execution.
ICU Medical currently trades at $184.88, up from $166.37 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free).
Now Could Be The Perfect Time To Invest In These Stocks
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.